![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_614c1c3b3daf287eb1f9dd78b5d06f2b.svg) | 4-Ethylphenylamino-1,2-dimethyl-6-methylaminopyrimidinium chloride | IC50 | 31.62 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_a462c0bfa1d0e2a99d0468fe87ed726c.svg) | Auglurant | IC50 | 100000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_878a482729b833a0834e68c7bbb1d6cd.svg) | 6-[[[1-[2-(7-Methoxy-2-oxoquinoxalin-1-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one | IC50 | 100000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_b4a5378c017ebc0e5783321865a04631.svg) | 2-Methoxy-N-{[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl}benzamide | IC50 | 5011.87 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_43f1811b8ff77f23f319df9e61cbb29f.svg) | CID 16015637 | IC50 | 50118.72 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_e08e9a12f804522a269ba4d2af435df1.svg) | 2-Methoxy-N-[2-(4-methylphenyl)-2-(4-methylpiperazin-1-yl)ethyl]benzamide | IC50 | 19952.62 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_1e827a90aeb1dd4eb6f47078d58ce2e8.svg) | 2-Ethoxy-N-[[1-(4-propan-2-ylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 316.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_a40938bed1de1e1dd8fc90e09e84d040.svg) | 2-Methoxy-N-[2-(4-methylpiperazin-1-yl)ethyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_214dc351bab751f5851a0f16625e74f4.svg) | 2-Ethoxy-N-{[1-(4-ethylpiperazin-1-yl)cyclohexyl]methyl}benzamide | IC50 | 158.49 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_49726121d49d268eff1d6e3ae83e344e.svg) | 2-Chloro-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 31622.78 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_492643e21965f811231b0e0bef5c33da.svg) | 2-Ethoxy-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 1258.93 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_654a583228a3abc76b4b394b8d1823d4.svg) | 2-[[[4-[(1R)-1-Amino-2-(7-fluoro-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one | IC50 | 100000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_40fb7ee3c708dc75c2de127920888869.svg) | 2-Ethoxy-N-((1-(piperazin-1-YL)cyclohexyl)methyl)benzamide | IC50 | 3981.07 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_e3ec7105138fc3743ede47426ad6ac88.svg) | 2-Methoxy-N-[(2-piperidin-1-yl-1,3-dihydroinden-2-yl)methyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_fbd4740f1f3e30e5133de1d55b43b351.svg) | 2-Ethoxy-N-[(1-piperidin-1-ylcyclohexyl)methyl]benzamide | IC50 | 39810.72 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_a0cf7bdbc0b75f37ddbba3b28b9b28b0.svg) | 2-Ethoxy-N-[[1-(4-methylpiperazin-1-yl)cyclopentyl]methyl]benzamide | IC50 | 5011.87 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_9d86b8d8853258377f625ed3b54069c8.svg) | 2-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 19952.62 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_f368cbb68b02ed72381576632782ea7c.svg) | N-[[2-(4-Methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]-2-phenylmethoxybenzamide | IC50 | 2511.89 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_9b6f0120b8d0141687ec9050b1a2a18a.svg) | N-[[2-(4-Methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]-2-(trifluoromethoxy)benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_cda51fde81e4005e5ca80271b932a97f.svg) | 2-Ethoxy-N-[[2-(4-propan-2-ylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 3162.28 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_c7d33bf8fa92e5146aa9ba91ed955ce1.svg) | 2-Ethoxy-N-[[4-(4-propan-2-ylpiperazin-1-yl)oxan-4-yl]methyl]benzamide | IC50 | 3981.07 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_d585bcbb754c40ede671a9cc9a0f5b6d.svg) | 2-Fluoro-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_d023729bd50544758ce9c41edded9f88.svg) | 2-Methyl-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_a2b4d4daccb46ea67d7e8a1c023186a4.svg) | N-[[1-(4-Cyclopropylpiperazin-1-yl)cyclohexyl]methyl]-2-ethoxybenzamide | IC50 | 316.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_81326c7ce0b5a337c6c58f60b3486a84.svg) | N-[[1-(4-Cyclobutylpiperazin-1-yl)cyclohexyl]methyl]-2-ethoxybenzamide | IC50 | 794.33 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_a610aecad51e40963a63cbbd229dae9c.svg) | 2-Methoxy-N-[[1-(4-propan-2-ylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 794.33 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_b770a0fffe8c98cc8ea950520d8fcefb.svg) | 2-Ethoxy-N-[[1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 100000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_ca896e6947ec195afdb0097a172b9a1b.svg) | 2-Ethoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 5011.87 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_2229fbb869604504f6f3650966ee88e9.svg) | 3-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_20843fbf84a5d0be9bba45d98bc9e5eb.svg) | 2-Chloro-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 158489.32 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_5110020b825deae4211e5fb3979d61ce.svg) | 2-Propan-2-yloxy-N-[[1-(4-propan-2-ylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 1584.89 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_f926671b64f1b2c8de9413db1a30f5a4.svg) | N-[[1-(4-Cyclopentylpiperazin-1-yl)cyclohexyl]methyl]-2-ethoxybenzamide | IC50 | 794.33 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_b0738fb3678caefd2e47b06dc06eb1b0.svg) | 2-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-3,4-dihydro-1H-naphthalen-2-yl]methyl]benzamide | IC50 | 6309.57 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_f63ed1a7f69bc418b631a82cdb1ff4e6.svg) | 2-Hydroxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_2b65d901615ee88c80e42755b98e38f4.svg) | 2-Methoxy-N-[[1-phenyl-4-(4-propan-2-ylpiperazin-1-yl)piperidin-4-yl]methyl]benzamide | IC50 | 5011.87 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_edaffb6da646038a2c5e7b0b8cc1d2ce.svg) | 4-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide | IC50 | 199526.23 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_e18e43de0987e4cacfd6c2a3680ce9cc.svg) | 2-Ethoxy-N-[(2-piperidin-1-yl-1,3-dihydroinden-2-yl)methyl]benzamide | IC50 | 39810.72 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_8474d992ab0ab06e91fc400de886b334.svg) | 2-Ethyl-N-[[1-(4-propan-2-ylpiperazin-1-yl)cyclohexyl]methyl]benzamide | IC50 | 79432.82 [1] |
![](https://images.aatbio.com/dataset/ic50/potassium-sodium-hyperpolarization-activated-cyclic-nucleotide-gated-channel-4_af21967b53bfd2b826ca060f1d6b9c87.svg) | N-[[1-[2-(Tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)piperidin-4-yl]methyl]-3,5-dichlorobenzamide | IC50 | 33000.0 [1] |